Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma
D Martínez Bedoya, V Dutoit, D Migliorini - Frontiers in immunology, 2021 - frontiersin.org
Chimeric antigen receptor (CAR) T cell therapy has emerged as one of the major
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
breakthroughs in cancer immunotherapy in the last decade. Outstanding results in …
sustainable clinical development of CAR-T cells–switching from viral transduction towards CRISPR-Cas gene editing
T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-
modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered …
modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered …
Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells
CRISPR-Cas9 genome editing has enabled advanced T cell therapies, but occasional loss
of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced …
of the targeted chromosome remains a safety concern. To investigate whether Cas9-induced …
Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes
CRISPR-mediated genome editing of primary human lymphocytes is typically carried out via
electroporation, which can be cytotoxic, cumbersome and costly. Here we show that the …
electroporation, which can be cytotoxic, cumbersome and costly. Here we show that the …
[HTML][HTML] Mapping the genetic landscape of DNA double-strand break repair
Cells repair DNA double-strand breaks (DSBs) through a complex set of pathways critical for
maintaining genomic integrity. To systematically map these pathways, we developed a high …
maintaining genomic integrity. To systematically map these pathways, we developed a high …
Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing
S Jo, S Das, A Williams, AS Chretien… - Nature …, 2022 - nature.com
Universal CAR T-cell therapies are poised to revolutionize cancer treatment and to improve
patient outcomes. However, realizing these advantages in an allogeneic setting requires …
patient outcomes. However, realizing these advantages in an allogeneic setting requires …
Cas9 exo-endonuclease eliminates chromosomal translocations during genome editing
The mechanism underlying unwanted structural variations induced by CRISPR-Cas9
remains poorly understood, and no effective strategy is available to inhibit the generation of …
remains poorly understood, and no effective strategy is available to inhibit the generation of …
AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines
L Zhang, JA Zuris, R Viswanathan, JN Edelstein… - Nature …, 2021 - nature.com
Though AsCas12a fills a crucial gap in the current genome editing toolbox, it exhibits
relatively poor editing efficiency, restricting its overall utility. Here we isolate an engineered …
relatively poor editing efficiency, restricting its overall utility. Here we isolate an engineered …
A highly efficient transgene knock-in technology in clinically relevant cell types
AG Allen, SQ Khan, CM Margulies… - Nature …, 2024 - nature.com
Inefficient knock-in of transgene cargos limits the potential of cell-based medicines. In this
study, we used a CRISPR nuclease that targets a site within an exon of an essential gene …
study, we used a CRISPR nuclease that targets a site within an exon of an essential gene …
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …